• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[Does SBRT still have a role to play in nodal oligorecurrent prostate cancer or is ENRT with ADT the new standard? : An interpretation of the PEACE V-STORM trial].

作者信息

Recknagel Niklas, Adeberg Sebastian

机构信息

Klinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Gießen und Marburg GmbH, Baldingerstraße, 35043, Marburg, Deutschland.

Marburger Ionenstrahl-Therapiezentrum (MIT), Universitätsklinikum Marburg, Marburg, Deutschland.

出版信息

Strahlenther Onkol. 2025 Sep 9. doi: 10.1007/s00066-025-02458-0.

DOI:10.1007/s00066-025-02458-0
PMID:40924121
Abstract
摘要

相似文献

1
[Does SBRT still have a role to play in nodal oligorecurrent prostate cancer or is ENRT with ADT the new standard? : An interpretation of the PEACE V-STORM trial].立体定向体部放疗在寡转移复发性前列腺癌中仍有作用吗？还是雄激素剥夺治疗联合外照射放疗是新的标准治疗方案？：对PEACE V-STORM试验的解读
Strahlenther Onkol. 2025 Sep 9. doi: 10.1007/s00066-025-02458-0.
2
PEACE V-Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 Trial.PEACE-V 挽救性治疗寡复发淋巴结转移前列腺癌（STORM）：一项随机 2 期试验的急性毒性。
Eur Urol Oncol. 2024 Jun;7(3):462-468. doi: 10.1016/j.euo.2023.09.007. Epub 2023 Oct 9.
3
Salvage metastasis-directed therapy versus elective nodal radiotherapy for oligorecurrent nodal prostate cancer metastases (PEACE V-STORM): a phase 2, open-label, randomised controlled trial.挽救性转移灶导向治疗与选择性淋巴结放疗用于寡复发性淋巴结前列腺癌转移（PEACE V-STORM）：一项2期、开放标签、随机对照试验
Lancet Oncol. 2025 Jun;26(6):695-706. doi: 10.1016/S1470-2045(25)00197-4. Epub 2025 May 5.
4
Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis.在转移性激素敏感性前列腺癌男性患者中，在雄激素剥夺治疗基础上加用阿比特龙：一项系统评价和荟萃分析。
Eur J Cancer. 2017 Oct;84:88-101. doi: 10.1016/j.ejca.2017.07.003. Epub 2017 Aug 8.
5
Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration-resistant prostate cancer in Canada (GROUQ-PCS 9): a multicentre, open-label, randomised, phase 2 trial.加拿大寡转移去势抵抗性前列腺癌标准全身治疗联合转移灶定向治疗（GROUQ-PCS 9）：一项多中心、开放标签、随机、2期试验
Lancet Oncol. 2025 Sep;26(9):1158-1167. doi: 10.1016/S1470-2045(25)00351-1.
6
EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.EAU 前列腺癌指南。第二部分：晚期、复发性和去势抵抗性前列腺癌的治疗。
Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12.
7
Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy.寡转移前列腺癌的转移灶导向治疗：立体定向体部放射治疗与选择性淋巴结放射治疗的疗效和毒性的多机构分析比较。
Eur Urol. 2019 Dec;76(6):732-739. doi: 10.1016/j.eururo.2019.07.009. Epub 2019 Jul 20.
8
Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol.对于开始接受雄激素剥夺治疗的转移性前列腺癌患者使用二甲双胍：STAMPEDE平台方案的一项随机3期试验
Lancet Oncol. 2025 Jul 7. doi: 10.1016/S1470-2045(25)00231-1.
9
Oligorecurrent Nodal Prostate Cancer: Long-term Results of an Elective Nodal Irradiation Approach.寡转移复发性淋巴结前列腺癌：选择性淋巴结照射方法的长期结果
Am J Clin Oncol. 2018 Oct;41(10):960-962. doi: 10.1097/COC.0000000000000419.
10
The role of radiotherapy in pelvic nodal recurrence following definitive treatment for prostate cancer.放射治疗在前列腺癌根治性治疗后盆腔淋巴结复发中的作用。
Curr Opin Urol. 2025 Sep 1;35(5):574-582. doi: 10.1097/MOU.0000000000001322. Epub 2025 Jul 17.

本文引用的文献

1
Salvage metastasis-directed therapy versus elective nodal radiotherapy for oligorecurrent nodal prostate cancer metastases (PEACE V-STORM): a phase 2, open-label, randomised controlled trial.挽救性转移灶导向治疗与选择性淋巴结放疗用于寡复发性淋巴结前列腺癌转移（PEACE V-STORM）：一项2期、开放标签、随机对照试验
Lancet Oncol. 2025 Jun;26(6):695-706. doi: 10.1016/S1470-2045(25)00197-4. Epub 2025 May 5.
2
ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial.雄激素剥夺疗法联合立体定向体部放疗与单纯立体定向体部放疗治疗激素敏感性寡转移复发性前列腺癌（RADIOSA）：一项随机、开放标签的2期临床试验。
Lancet Oncol. 2025 Mar;26(3):300-311. doi: 10.1016/S1470-2045(24)00730-7.
3
Pelvis Or Involved Node Treatment: Eradicating Recurrence in Prostate Cancer (POINTER-PC) - study protocol paper for a phase III multicentre, open-label randomised controlled trial.骨盆或受累淋巴结治疗：前列腺癌复发的根除（POINTER-PC）——一项III期多中心、开放标签随机对照试验的研究方案论文
BMJ Open. 2024 Dec 26;14(12):e095560. doi: 10.1136/bmjopen-2024-095560.
4
Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial.68Ga-PSMA-11 PET 对根治性前列腺切除术和盆腔淋巴结清扫术前盆腔淋巴结转移检测的诊断准确性：一项多中心前瞻性 3 期影像学试验。
JAMA Oncol. 2021 Nov 1;7(11):1635-1642. doi: 10.1001/jamaoncol.2021.3771.
5
Combining Ga-PSMA-PET/CT-Directed and Elective Radiation Therapy Improves Outcome in Oligorecurrent Prostate Cancer: A Retrospective Multicenter Study.联合镓-前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描引导放疗与选择性放疗可改善寡转移复发性前列腺癌的预后：一项回顾性多中心研究
Front Oncol. 2021 May 10;11:640467. doi: 10.3389/fonc.2021.640467. eCollection 2021.
6
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.多西他赛、唑来膦酸或两者联合添加至前列腺癌一线长期激素治疗（STAMPEDE）：一项适应性、多组、多阶段、平台随机对照试验的生存结果
Lancet. 2016 Mar 19;387(10024):1163-77. doi: 10.1016/S0140-6736(15)01037-5. Epub 2015 Dec 21.
7
Duration of androgen suppression in the treatment of prostate cancer.雄激素抑制在前列腺癌治疗中的持续时间。
N Engl J Med. 2009 Jun 11;360(24):2516-27. doi: 10.1056/NEJMoa0810095.
8
Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer.放射肿瘤学组92 - 02方案的十年随访：局部晚期前列腺癌选择性雄激素剥夺持续时间的III期试验
J Clin Oncol. 2008 May 20;26(15):2497-504. doi: 10.1200/JCO.2007.14.9021. Epub 2008 Apr 14.